| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 13/01/2025 | 08:05 | Business Wire | GSK Enters Agreement to Acquire IDRx, Inc. | NYSE:GSK | GSK plc |
| 02/01/2025 | 16:07 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:GSK | GSK plc |
| 09/12/2024 | 19:38 | Business Wire | Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse | NYSE:GSK | GSK plc |
| 30/10/2024 | 11:35 | IH Market News | Google Cloud Revenue Grows 35%; AMD Stock Drops 8%, Qorvo Plummets 18%, Reddit Surges 24% in Pre-Market | NYSE:GSK | GSK plc |
| 24/10/2024 | 13:00 | Business Wire | New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease | NYSE:GSK | GSK plc |
| 14/10/2024 | 12:11 | IH Market News | TSMC To Exceed Profits, Plans European Factories; Boeing Cuts 17,000 Jobs; Berkshire Boosts Sirius XM Stake | NYSE:GSK | GSK plc |
| 10/10/2024 | 12:45 | IH Market News | Tesla’s Robotaxi Day; GSK Settles 93% of Zantac Lawsuits; 10x Genomics Stock Drops on Revenue Forecast | NYSE:GSK | GSK plc |
| 08/10/2024 | 13:00 | Business Wire | GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons | NYSE:GSK | GSK plc |
| 03/10/2024 | 14:45 | InvestorsHub NewsWire | Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More | NYSE:GSK | GSK plc |
| 19/09/2024 | 14:00 | GlobeNewswire Inc. | Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024) | NYSE:GSK | GSK plc |
| 19/09/2024 | 12:26 | IH Market News | AIG names new CFO; Progyny Drops 24% After Losing Key 2025 Contract; Exicure Jumps 190% With Nasdaq Extension | NYSE:GSK | GSK plc |
| 18/09/2024 | 13:00 | Business Wire | GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX | NYSE:GSK | GSK plc |
| 16/09/2024 | 19:04 | PR Newswire (US) | Brooke Shields Partners with GSK to Educate Adults 50 and Older About Their Shingles Risk | NYSE:GSK | GSK plc |
| 11/09/2024 | 12:25 | IH Market News | GameStop plunges 11% on stock offering, DJT drops post-debate, GSK fails shingles vaccine trial | NYSE:GSK | GSK plc |
| 28/08/2024 | 11:50 | IH Market News | High Volatility Expected in Nvidia Report, Ambarella Soars 20%, Hertz Strengthens Board, Apple Cuts Jobs | NYSE:GSK | GSK plc |
| 06/08/2024 | 22:05 | GlobeNewswire Inc. | Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% | NYSE:GSK | GSK plc |
| 01/08/2024 | 21:44 | Business Wire | US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit | NYSE:GSK | GSK plc |
| 30/07/2024 | 12:03 | IH Market News | F5 Shares Rise 15%; Diageo Falls 10% on Annual Sales Decline; BP Boosts Dividend and Buyback Program | NYSE:GSK | GSK plc |
| 29/07/2024 | 12:24 | IH Market News | Apple Delays AI Features, Abbott Shares Plunge 7% After $495M Fine, Philips Soars 10% | NYSE:GSK | GSK plc |
| 11/07/2024 | 14:00 | Business Wire | GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season | NYSE:GSK | GSK plc |
| 03/07/2024 | 12:59 | IH Market News | Apple Joins OpenAI Board, Logitech President Opts Out of Reelection, and More News | NYSE:GSK | GSK plc |
| 27/06/2024 | 13:13 | IH Market News | Interactive Brokers Loses $48 Million on NYSE, Amazon Achieves Historic Market Value, and More News | NYSE:GSK | GSK plc |
| 08/06/2024 | 00:57 | Business Wire | US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk | NYSE:GSK | GSK plc |
| 03/06/2024 | 14:10 | Business Wire | Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer | NYSE:GSK | GSK plc |
| 02/06/2024 | 16:56 | Business Wire | Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma | NYSE:GSK | GSK plc |
| 21/05/2024 | 13:18 | IH Market News | CalPERS to Oppose Exxon Mobil Directors; Microsoft Unveils Copilot+ PCs with AI Focus, and More News | NYSE:GSK | GSK plc |
| 17/05/2024 | 13:36 | IH Market News | OpenAI’s Reddit Partnership Boosts Shares by 14%, Microsoft Embraces AMD Chips for AI, and More News | NYSE:GSK | GSK plc |
| 07/05/2024 | 07:00 | GlobeNewswire Inc. | BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million | NYSE:GSK | GSK plc |
| 26/04/2024 | 13:48 | IH Market News | Anglo American Rejects BHP Group’s Offer, Toyota Invests $1.4 Billion in Indiana, and More News | NYSE:GSK | GSK plc |
| 16/03/2024 | 13:00 | Business Wire | Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer | NYSE:GSK | GSK plc |